AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...

Several of these commercialized cell therapies have emerged as top-selling drugs in the healthcare sector. For example, Gilead Sciences reported that Yescarta achieved sales exceeding USD 1.5 billion, ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

With rapid innovations in biotechnology, companies are developing groundbreaking therapies and diagnostic tools that address ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Wesley Sundquist, Ph.D., chair of the Department of Biochemistry, was awarded the 2024 Louisa Gross Horwitz Prize.

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

Defendant Yisel Lopez has been found in contempt for violating an asset freeze order through the sale of property.

Although details are scant, Shanghai Fosun Pharmaceutical Co. Ltd. plans to buy out partner Kite Pharma Inc. (now Gilead Sciences Inc.) in the Fosun Pharma Kite Biotechnology Co. Ltd. joint venture ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

Jackson Egen learned the value of basic lab research as a graduate student at UC Berkeley in the 90s while working under the ...